PARIS–(BUSINESS WIRE)–Regulatory News: Advicenne (Euronext Growth Paris – FR0013296746 – ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, today reports its 2026 first half financial results, as approved on September 17, 2026, by the Board of Directors. The first half financial report is available on the Company’s website: www.advicenne.com. Didier Laurens, Chief Executive Officer of Advicenn